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A b s t r a c t
Introduction: The aim of our study was to evaluate the diagnostic charac-
teristics of selected inflammatory markers and the results of multiplication 
of their concentrations in the diagnosis and assessment of Crohn’s disease 
(CD) activity.
Methods: We studied 49 patients with CD and 31 healthy controls. The CD 
patients were assigned to subgroups with active and inactive disease based 
on the Crohn’s Disease Activity Index score. Serum interleukins and C-reac-
tive protein (CRP) were measured using immunoassays. 
Results: Serum CRP and interleukins: IL-6, IL-17A, IL-23 were significantly 
higher in the CD group than in controls, with the best diagnostic perfor-
mance for IL-23. Only serum IL-6 and CRP were significantly higher in active 
than in inactive disease, with the better performance of CRP. Multiplication 
results did not perform better than individual multipliers. 
Conclusions: Serum CRP may be useful in the assessment of CD activity and 
there is a need for introduction of IL-23 for the CD diagnosis.
Key words: inflammatory bowel disease, cytokines, C-reactive protein, 
Crohn’s disease activity index.
Crohn’s disease (CD) is a chronic transmural intestinal inflammation 
affecting various parts of the gastrointestinal tract. Diagnosis of CD is 
based on the history and physical examination, imaging studies includ-
ing magnetic resonance, endoscopy and histology, and laboratory tests 
[1, 2].
Laboratory tests are additional tools in the CD diagnosis and include 
antibodies to Saccharomyces cerevisiae and inflammatory markers such 
as erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP) 
or interleukin 6 (IL-6), and fecal calprotectin (FC). Except for FC, inflam-
matory markers are not routinely used in the diagnosis of CD. However, 
under certain clinical circumstances, these markers may be helpful in 
differentiating inflammatory bowel disease (IBD) from non-inflammatory 
disorders such as irritable bowel syndrome and in establishing a further 
diagnostic strategy. 
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The clinical status of CD patients is often as-
sessed using the Crohn’s Disease Activity Index 
(CDAI) calculated using clinical and laboratory data 
including general well-being, number of abnormal 
stools, abdominal pain, arthritis/arthralgia, muco-
cutaneous lesions, iritis/uveitis, fever, hematocrit 
and others [3]. However, some criteria included in 
the CDAI are scored by the patients subjectively and 
some of them may require extended diagnostics, 
e.g. eyes examination or osteoarticular assessment. 
Therefore, the use of CDAI can be time consuming, 
inconvenient for the patient and sometimes not 
completely reliable. Another approach is endoscopy 
and cross-sectional imaging techniques with the 
use of ultrasound, computed tomography and mag-
netic resonance imaging. However, these diagnostic 
procedures have several disadvantages [4, 5]. As in-
flammation plays a key role in the pathogenesis and 
clinical course of CD, the use of inflammatory mark-
ers is another option in assessing disease activity.
Fecal calprotectin and serum CRP are broadly 
studied and used for CD activity assessment in 
clinical practice [6, 7]. However, IL-6, IL-17A and 
IL-23 (IL-23/IL-17 axis), despite their well-doc-
umented role in triggering and maintaining the 
mucosal inflammation, still remain candidate 
markers. The availability of simple laboratory tests 
instead of quite complicated scoring systems and/
or endoscopy could make CD activity assessment 
easier and faster. Many approaches to use bio-
markers for this purpose have been studied with 
conflicting results [4, 5, 8–12]. 
In this study, we aimed to evaluate the diag-
nostic characteristics of selected inflammatory 
markers including serum CRP, IL-6, IL-17A, IL-23, 
and the results (products) of multiplication of their 
concentrations in the diagnosis of CD and in the 
assessment of disease activity.
Methods. We studied 49 patients with CD, 
aged from 22 to 50 years and 31 healthy con-
trols aged from 20 to 61 years. The study was 
conducted in years 2018–2019 and the patients 
were enrolled consecutively in the Department of 
Gastroenterology and Hepatology of the Univer-
sity Hospital, Krakow, Poland. The diagnosis of 
CD was based on the patient’s history, physical 
examination and colonoscopy with histology. All 
CD patients studied were treated at the time of 
enrollment. The therapies used included gluco-
corticoids, 6-mercaptopurine, 5-aminosalicylate, 
Infliximab and antibiotics. In all CD patients the 
CDAI score was calculated and they were assigned 
to subgroups with active (CDAI score ≥ 150, 
33 patients) and inactive (CDAI score < 150, 16 pa- 
tients) disease. Informed consent was signed by 
each subject prior to enrolling in the study. The 
Bioethical Committee of the Jagiellonian Universi-
ty, Krakow, Poland, approved the study. 
Serum concentrations of IL-6, IL-17A and IL-23 
were measured using ELISA reagent kits. High-sen-
sitivity C-reactive protein (hs-CRP) was measured 
using the immunonephelometric assay on the 
Nephelometer II Analyzer (Siemens Healthcare Di-
agnostics). The results of multiplication of concen-
trations: [IL-6] × [CRP], [IL-17A] × [CRP], [IL-23] × 
[CRP], [IL-6] × [IL-17A], [IL-6] × [IL-23] and [IL-17A] 
× [IL-23] were calculated using standard units 
(mg/l for CRP, pg/ml for interleukins).
Statistical analysis. Data distribution was analyzed 
using the Shapiro-Wilk test. All variables in our study 
showed a nonparametric distribution, and therefore 
the results are presented as medians and interquar-
tile ranges [Q1-Q3]. Medians were compared using 
the Kruskal-Wallis Anova test and the Dunn Test. The 
significance level of p < 0.05 was applied. 
Diagnostic characteristics in differentiating be-
tween the presence and absence of CD and be-
tween active and inactive disease were assessed 
using Receiver Operating Characteristics (ROC) 
curve analysis to select appropriate cut-off val-
ues and calculations of diagnostic sensitivity and 
specificity, positive and negative predictive value, 
and area under the ROC curve (AUC). All analyzes 
were performed using the Statistica 13 software 
(StatSoft Poland).
Results. Serum levels of CRP, IL-6, IL-17A and 
IL-23 were significantly higher in the CD group than 
in controls (Table I). In the diagnosis of CD, IL-23 
had the most favorable diagnostic characteristics 
while other markers performed worse with AUC 
< 0.8 (Table II). All results (products) of multipli-
cation of concentrations differed significantly be-
tween CD patients and the control group (Table I). 
The diagnostic characteristics of these products 
were better than those of the individual factors, 
but still the best performance was found for serum 
IL-23 multiplied by CRP, IL-6 and IL-17A levels. Also, 
the performance of [IL-6] × [CRP] was slightly bet-
ter than that of IL-6 and CRP separately (Table II).
In the group of patients with CD, only serum 
CRP and IL-6 were significantly higher in active 
than in inactive disease (Table I). In differentiating 
active and inactive CD with cut-off values other 
than for the diagnosis, the best diagnostic per-
formance was found for CRP whereas IL-6, IL-17A 
and IL-23 performed worse. The multiplication of 
serum levels slightly improved their diagnostic 
performance as combined markers (Table II).
Discussion. In this study, we evaluated CRP and 
inflammatory cytokines reported to be associated 
with CD pathogenesis and clinical course, i.e. IL-6, 
IL-17A, IL-23 and the results of multiplication of 
their concentrations as combined markers in the 
CD diagnosis and disease activity assessment. 
We observed serum CRP levels as well as the 
results of multiplications: [IL-6] × [CRP], [IL-17A] × 
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[CRP], [IL-23] × [CRP] significantly higher in the CD 
group than in controls (Table I). However, the per-
formance of serum CRP in the diagnosis of CD was 
rather poor and only slightly improved after multi-
plication by IL-6, IL-17A and IL-23 levels (Table II). 
These findings seem to exclude the use of CRP in 
the diagnosis of CD. However, the slight differenc-
es in serum CRP between the studied group and 
controls (Table I) and the observed poor diagnostic 
performance were largely due to by the CD treat-
ment of patients studied, which is a limitation of 
this analysis. 
Serum CRP and FC are the most broadly eval-
uated and frequently used markers of CD activity 
[5, 6, 13]. Increased serum CRP levels were report-
ed in patients with CD and associated with the 
disease activity [2, 6, 14, 15]. In our study, serum 
CRP was significantly higher in CD patients with 
active than with inactive disease (Table I). CRP had 
diagnostic sensitivity of 0.72, which means 72% 
agreement with the CDAI, diagnostic specificity 
and PPV equal to 1.0 and good overall performance 
(Table II). Multiplication of serum CRP by IL-6, 
IL-17A and IL-23 levels did not improve diagnos-
tic characteristics of these combined markers. It 
is noteworthy that similar diagnostic performance 
was reported for FC [16–18].
Diagnostic performance of CRP found in our 
study was close to reported in comparison with 
endoscopic assessment of CD activity [19], when 
combined with FC for selecting patients with sus-
pected CD of the small bowel for capsule endos-
copy [20] and together with CDAI and fecal cal-
protectin to predict the outcome after anti-tumor 
necrosis factor (TNF) induction therapy [21]. Alto-
gether, our and published data indicate that serum 
CRP reliably assesses the clinical activity of CD.
IL-6 is considered a central cytokine in the CD 
pathogenesis and propagation [22, 23]. We found 
that its serum levels as well as the results of mul-
Table I. Comparison of median values (IQR) of serum inflammatory makers and the results of multiplication of their 
concentrations in CD patients and controls and in patients with active and inactive CD
Marker Crohn’s disease (n = 49) Control group (n = 31) P-value
Median (IQR)
CRP [mg/l] 3.48 (1.03–20.62) 0.51 (0.16–1.74) 0.0001
IL-6 [pg/ml] 3.24 (1.50–7.35) 1.35 (0.77–1.96) < 0.0001
IL-17A [pg/ml] 2.01 (1.26–3.48) 0.93 (0.47–1.88) 0.0001
IL-23 [pg/ml] 23.3 (18.0–36.0) 5.78 (3.70–7.79) < 0.0001
[IL-6] × [CRP] 17.8 (1.38–111.39) 0.35 (0.00–8.34) < 0.0001
[IL-17A] × [CRP] 7.18 (1.30–40.92) 0.35 (0.00–8.34) < 0.0001
[IL-23] × [CRP] 108.22 (16.76–579.80) 2.47 (0.70–10.32) < 0.0001
[IL-6] × [IL-17A] 6.51 (2.50–17.39) 1.49 (0.01–15.42) < 0.0001
[IL-6] × [IL-23] 93.53 (32.86–227.93) 6.71 (4.01–13.44) < 0.0001
[IL-17A] × [IL-23] 52.10 (30.07–109.40) 4.43 (2.25–10.75) < 0.0001
Marker Inactive CD 
CDAI < 150 (n = 16)
Active CD 
CDAI ≥ 150 (n = 33)
P-value
CRP [mg/l] 1.14 (0.46–2.56) 10.85 (2.96–28.12) 0.000130
IL-6 [pg/ml] 2.05 (1.01–3.20) 4.35 (2.16–9.00) 0.025885
IL-17A [pg/ml] 2.01 (1.23–3.34) 2.01 (1.26–3.70) 0.639040
IL-23 [pg/ml] 20.90 (16.54–26.82) 26.65 (19.36–37.04) 0.132823
[IL-6] × [CRP] 2.39 (0.02–24.66) 41.38 (0.04–3388.08) < 0.0001
[IL-17A] × [CRP] 2.13 (0.50–24.92) 19.97 (0.02–557.33) < 0.0001
[IL-23] × [CRP] 21.66 (9.33–51.68) 422.15 (68.19–790.87) < 0.0001
[IL-6] × [IL-17A] 4.40(0.33–35.24) 7.53 (0.12–510.44) < 0.0001
[IL-6] × [L-23] 43.93 (27.62–103.60) 114.26 (42.91–268.33) < 0.0001
[IL-17A] × [IL-23] 37.10 (23.13–83.97) 59.37 (33.19–151.79) < 0.0001
CD – Crohn’s disease, CDAI – Crohn’s disease activity index, IQR – interquartile range.
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tiplication of concentrations were significantly 
higher in patients with CD than in controls. The 
performance of IL-6 in the CD diagnosis was bet-
ter than CRP and multiplication [IL-6] × [CRP] im-
proved it slightly but still with AUC < 0.8 (Table II). 
With a similar limitation as in the case of CRP, the 
overall diagnostic performance of IL-6 is inferior to 
that required for clinical practice purposes.
IL-6 is also a  candidate marker for CD course 
and treatment monitoring. It was demonstrated 
to be associated with disease activity [22–25], to 
predict endoscopic IBD activity in combination 
with serum amyloid A  (SAA), IL-8, and eotaxin-1 
[26], and to predict the response to biologic treat-
ment in CD patients [27, 28]. However, there are 
also reports that do not confirm the diagnostic 
utility of IL-6 in CD [29]. We found serum IL-6 sig-
nificantly higher in CD patients with active than 
inactive disease (Table I). The ratio of median 
serum IL-6 in active and inactive CD of 2.12 was 
similar to that reported by Mavropoulou et al. [25], 
but lower than in a study by Nikolaus et al. [24]. 
Diagnostic performance of IL-6 in differentiating 
active and inactive disease was in our study worse 
than that of CRP (Table II).
CRP is synthetized and secreted by hepatocytes 
under the influence of IL-6, and their serum levels 
usually correlate. We evaluated diagnostic char-
acteristics of the results of multiplication [IL-6] × 
[CRP]. The values of this combined marker differed 
significantly between patients with active and in-
active CD, and its diagnostic performance was bet-
ter than that of IL-6 but worse than that of CRP 
(Tables I, II). In conclusion, contrary to the pub-
lished data mentioned above, IL-6 is not a suitable 
single marker also for the differentiation of active 
and inactive CD.
Th17 cells and the IL-17/IL-23 axis play an 
important role in the pathogenesis and clinical 
course of CD [30, 31]. Additionally, IL-6 and IL-17 
are inflammatory mediators produced by acti-
vated Th17 cells [32]. However, evidence for the 
Table II. Diagnostic characteristics of serum inflammatory markers and the results of multiplication of their con-
centrations in the diagnosis of CD and the differentiation of active and inactive disease
Marker Cut-off value Sensitivity Specificity PPV NPV AUC
The diagnosis of CD:
CRP [mg/l] 2.69 0.592 0.933 0.935 0.583 0.761
IL-6 [pg/ml] 2.16 0.673 0.839 0.868 0.619 0.765
IL-17A [pg/m] 1.06 0.878 0.548 0.754 0.739 0.757
IL-23 [pg/ml] 15.02 0.959 0.968 0.979 0.938 0.994
[IL-6] × [CRP] 12.7 0.571 1.000 1.000 0.596 0.791
[IL-17A] × [CRP] 3.3 0.694 0.935 0.944 0.659 0.846
[IL-23] × [CRP] 29.1 0.735 1.000 1.000 0.705 0.904
[IL-6] × [IL-17A] 2.5 0.776 0.774 0.844 0.686 0.799
[IL-6] × [L-23] 16.9 0.898 0.935 0.957 0.853 0.939
[IL-17A] × [IL-23] 21.4 0.857 0.935 0.955 0.806 0.947
The differentiation of active and inactive disease:
CRP [mg/l] 4.54 0.72 1.00 1.00 0.64 0.841
IL-6 [pg/ml] 2.78 0.70 0.75 0.85 0.55 0.699
IL-17A [pg/ml] 0.99 0.94 0.19 0.71 0.60 0.543
IL-23 [pg/ml] 15.5 0.97 0.19 0.71 0.75 0.634
[IL-6] × [CRP] 19.6 0.70 0.94 0.96 0.60 0.801
[IL-17A] × [CRP] 7.2 0.73 0.94 0.96 0.63 0.822
[IL-23] × [CRP] 0.77 1.00 0.06 0.69 1.00 0.854
[IL-6] × [IL-17A] 0.80 0.94 0.25 0.72 0.67 0.618
[IL-6] × [L-23] 50.1 0.73 0.63 0.80 0.53 0.712
[IL-17A] × [IL-23] 12.7 0.97 0.13 0.70 0.67 0.616
CD – Crohn’s disease, NPV – negative predictive value, PPV – positive predictive value, AUC – area under the ROC curve.
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diagnostic utility of IL-17 and IL-23 in CD/IBD is 
scarce and reports are discordant [33–35]; more 
attention is paid to these cytokines as a  thera-
peutic target [36, 37]. In our study, serum IL-17A 
and IL-23 as well as the results of multiplication 
of their concentrations were significantly higher 
in treated CD patients compared to controls. In 
the diagnosis of CD serum IL-23 performed best 
among all studied markers, while the diagnos-
tic characteristics of IL-17A were comparable to 
those of IL-6 (Table I). The diagnostic performance 
of the multiplication results was markedly better 
than that of serum CRP and IL-6 but still slightly 
worse than with IL-23 as a single marker (Table II). 
The diagnostic performance of IL-23 may be relat-
ed to the involvement of the IL-17/IL-23 axis in CD 
pathogenesis. However, this was not the case with 
IL-17A and IL-6.
Interestingly, serum levels of IL-17A and IL-23 
did not differ significantly between CD patients 
with active and inactive disease, but their multipli-
cation results did (Table I). The performance of IL-
17A and IL-23 in differentiating active and inactive 
CD was poor (Table II). Multiplying serum levels of 
IL-17A and IL-23 by CRP made the diagnostic per-
formance of these combined markers comparable 
to CRP (Table II). Thus, both IL-17A and IL-23 can-
not be recommended as markers of CD activity.
Laboratory markers of inflammation are hardly 
used in the diagnosis of CD and the assessment 
of its activity. We found good performance char-
acteristics of IL-23 in the diagnosis of CD and CRP 
in the assessment of disease activity. We also 
evaluated the results of multiplication of concen-
trations as combined inflammatory markers, but 
their diagnostic performance was not better com-
pared to the individual multipliers to a degree au-
thorizing their use in clinical practice.
Measurement of inflammatory markers in se-
rum can be performed together with other tests 
necessary for care of CD patients, such as complete 
blood count or serum albumin. In general, laborato-
ry markers used instead of or in selecting patients 
for endoscopy or other imaging studies could make 
the CD diagnosis and the assessment of its activ-
ity easier, more convenient and less expensive. 
Promising diagnostic performance of CRP and IL-23 
found in our study in a relatively small group of CD 
patients should be considered preliminary. It has to 
be emphasized, however, that currently CRP is mea-
sured routinely, while the IL-23 ELISA reagent kits 
are approved for research use only. Thus, our results 
suggest the utility of serum CRP in assessment of 
CD activity, and the need for validation and approv-
al of IL-23 assays for the CD diagnosis. 
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